Bupropion-SR for smoking reduction and cessation in alcohol-dependent outpatients: A naturalistic, open-label study

Maher Karam-Hage, Jason D. Robinson, Ashutosh Lodhi, Kirk J. Brower

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: We sought to determine whether sustained-release bupropion (bupropion-SR) reduces smoking and promotes smoking cessation among alcohol-dependent (AD) smokers while they are in early recovery from alcohol. Methods: We conducted an open-label, naturalistic study among AD smokers enrolled in an outpatient treatment program. The treatment group (n=58) was offered bupropion-SR and brief smoking cessation counseling. A control group (n=57) was matched to the treatment group by age, sex, ethnicity, cigarette use, and years of alcohol dependence. The controls received no smoking cessation intervention. We collected tobacco and alcohol abstinence data for 6 months after enrollment. Results: Participants in the treatment group were more likely to abstain from smoking than controls, at any of the followup time points. The treatment group smoked less cigarettes per day (CPD) at baseline, 30 days and 180 days post-baseline, compared to controls. These findings persisted after adjusting for possible covariates. Conclusion: Bupropion-SR may be helpful to quit or reduce smoking for recently abstinent AD individuals.

Original languageEnglish (US)
Pages (from-to)123-129
Number of pages7
JournalCurrent Clinical Pharmacology
Volume9
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Bupropion
Smoking Cessation
Outpatients
Alcohols
Smoking
Tobacco Products
Alcohol Abstinence
Therapeutics
Alcoholism
Tobacco
Counseling
Age Groups
Control Groups

Keywords

  • Alcohol dependence
  • Bupropion
  • Cessation
  • Nicotine
  • Smoking
  • Treatment

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Bupropion-SR for smoking reduction and cessation in alcohol-dependent outpatients : A naturalistic, open-label study. / Karam-Hage, Maher; Robinson, Jason D.; Lodhi, Ashutosh; Brower, Kirk J.

In: Current Clinical Pharmacology, Vol. 9, No. 2, 01.01.2014, p. 123-129.

Research output: Contribution to journalArticle

@article{a1e43dd23dd34bf0bee564cac9b3f109,
title = "Bupropion-SR for smoking reduction and cessation in alcohol-dependent outpatients: A naturalistic, open-label study",
abstract = "Background: We sought to determine whether sustained-release bupropion (bupropion-SR) reduces smoking and promotes smoking cessation among alcohol-dependent (AD) smokers while they are in early recovery from alcohol. Methods: We conducted an open-label, naturalistic study among AD smokers enrolled in an outpatient treatment program. The treatment group (n=58) was offered bupropion-SR and brief smoking cessation counseling. A control group (n=57) was matched to the treatment group by age, sex, ethnicity, cigarette use, and years of alcohol dependence. The controls received no smoking cessation intervention. We collected tobacco and alcohol abstinence data for 6 months after enrollment. Results: Participants in the treatment group were more likely to abstain from smoking than controls, at any of the followup time points. The treatment group smoked less cigarettes per day (CPD) at baseline, 30 days and 180 days post-baseline, compared to controls. These findings persisted after adjusting for possible covariates. Conclusion: Bupropion-SR may be helpful to quit or reduce smoking for recently abstinent AD individuals.",
keywords = "Alcohol dependence, Bupropion, Cessation, Nicotine, Smoking, Treatment",
author = "Maher Karam-Hage and Robinson, {Jason D.} and Ashutosh Lodhi and Brower, {Kirk J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/1574884708666131112124429",
language = "English (US)",
volume = "9",
pages = "123--129",
journal = "Current Clinical Pharmacology",
issn = "1574-8847",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Bupropion-SR for smoking reduction and cessation in alcohol-dependent outpatients

T2 - A naturalistic, open-label study

AU - Karam-Hage, Maher

AU - Robinson, Jason D.

AU - Lodhi, Ashutosh

AU - Brower, Kirk J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: We sought to determine whether sustained-release bupropion (bupropion-SR) reduces smoking and promotes smoking cessation among alcohol-dependent (AD) smokers while they are in early recovery from alcohol. Methods: We conducted an open-label, naturalistic study among AD smokers enrolled in an outpatient treatment program. The treatment group (n=58) was offered bupropion-SR and brief smoking cessation counseling. A control group (n=57) was matched to the treatment group by age, sex, ethnicity, cigarette use, and years of alcohol dependence. The controls received no smoking cessation intervention. We collected tobacco and alcohol abstinence data for 6 months after enrollment. Results: Participants in the treatment group were more likely to abstain from smoking than controls, at any of the followup time points. The treatment group smoked less cigarettes per day (CPD) at baseline, 30 days and 180 days post-baseline, compared to controls. These findings persisted after adjusting for possible covariates. Conclusion: Bupropion-SR may be helpful to quit or reduce smoking for recently abstinent AD individuals.

AB - Background: We sought to determine whether sustained-release bupropion (bupropion-SR) reduces smoking and promotes smoking cessation among alcohol-dependent (AD) smokers while they are in early recovery from alcohol. Methods: We conducted an open-label, naturalistic study among AD smokers enrolled in an outpatient treatment program. The treatment group (n=58) was offered bupropion-SR and brief smoking cessation counseling. A control group (n=57) was matched to the treatment group by age, sex, ethnicity, cigarette use, and years of alcohol dependence. The controls received no smoking cessation intervention. We collected tobacco and alcohol abstinence data for 6 months after enrollment. Results: Participants in the treatment group were more likely to abstain from smoking than controls, at any of the followup time points. The treatment group smoked less cigarettes per day (CPD) at baseline, 30 days and 180 days post-baseline, compared to controls. These findings persisted after adjusting for possible covariates. Conclusion: Bupropion-SR may be helpful to quit or reduce smoking for recently abstinent AD individuals.

KW - Alcohol dependence

KW - Bupropion

KW - Cessation

KW - Nicotine

KW - Smoking

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84921425063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921425063&partnerID=8YFLogxK

U2 - 10.2174/1574884708666131112124429

DO - 10.2174/1574884708666131112124429

M3 - Article

C2 - 24218993

AN - SCOPUS:84921425063

VL - 9

SP - 123

EP - 129

JO - Current Clinical Pharmacology

JF - Current Clinical Pharmacology

SN - 1574-8847

IS - 2

ER -